Open AccessHepatocellular Carcinoma: Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy (Adv. Sci. 5/2021)
Author(s) -
Xu Shengjun,
Ling Sunbin,
Shan Qiaonan,
Ye Qianwei,
Zhan Qifan,
Jiang Guangjiang,
Zhuo Jianyong,
Pan Binhua,
Wen Xue,
Feng Tingting,
Lu Haohao,
Wei Xuyong,
Xie Haiyang,
Zheng Shusen,
Xiang Jiajia,
Shen Youqing,
Xu Xiao
Publication year - 2021
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202170022
Subject(s) - sorafenib , hepatocellular carcinoma , small hairpin rna , cancer research , liver cancer , medicine , oncology , chemistry , apoptosis , biochemistry , gene knockdown
Resistance to sorafenib remains one of the biggest concerns for hepatocellular carcinoma treatment. In article number 2003042, Xiao Xu, Jiajia Xiang, and co‐workers developed a self‐activated sorafenib and USP22 shRNA codelivery nanoplatform (Gal‐SLP) to reverse cancer stemness and sensitive cancer cells to sorafenib. Gal‐SLP releases USP22 shRNA efficiently and enhances the intracellular sorafenib accumulation in cancer cells. Gal‐SLP exhibits potent antitumor efficiency in a sorafenibinsensitive patient‐derived xenograft (PDX) model.